Every 10-Q that McKesson Corporation (MCK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MCK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCK filings page.
McKesson Corporation reported first‑quarter fiscal 2027 revenue of $105,380 million, up from $97,827 million a year earlier, with growth across all segments, especially Oncology & Multispecialty. Operating income increased to $1,319 million and consolidated net income to $1,032 million.
Net income attributable to McKesson fell to $614 million, or diluted earnings per share of $5.15, from $784 million and $6.25, reflecting substantially higher income allocated to noncontrolling interests and a $374 million redemption value adjustment on redeemable noncontrolling interests tied to recent oncology and Medical‑Surgical transactions. Operating cash flow was an outflow of $220 million, mainly from higher receivables and inventory, while cash and cash equivalents rose to $5,164 million.
Long‑term debt including current maturities increased to $9,729 million following new secured term loans at the Medical‑Surgical Solutions subsidiary, and McKesson maintained a $5,000 million undrawn corporate revolving facility. The company recorded $136 million of restructuring, impairment, and related charges and ended the quarter with $5,660 million of litigation liabilities associated with opioid‑related matters. Capital returns remained significant, with $2,530 million of share repurchases and $0.82 per‑share dividends in the quarter, and the quarterly dividend was raised to $0.94 per share in July 2026.
McKesson Corporation reports stronger results for the quarter ended December 31, 2025, with revenue rising to $106,158 million from $95,294 million and net income attributable to McKesson increasing to $1,186 million from $879 million. Diluted earnings per share grew to $9.59 from $6.95 as operating income rose to $1,619 million.
For the nine months, revenue reached $307,135 million and net income attributable to McKesson was $3,080 million, up from $2,035 million. The company completed major acquisitions of Vision Holdings and Core Ventures, adding significant goodwill and intangibles, funded partly by a $2.0 billion public debt offering.
McKesson ended the period with $2,959 million in cash and cash equivalents, total debt of $6,557 million, and opioid-related litigation liabilities of $5,708 million. Operating cash flow improved to $2,734 million for the nine months, while substantial share repurchases and dividends continued alongside ongoing restructuring and technology modernization initiatives.
McKesson Corporation reported stronger Q2 FY26 results. Revenue reached $103.15 billion, up from $93.65 billion a year ago, lifting gross profit to $3.54 billion. Operating income rose to $1.41 billion and net income attributable to McKesson increased to $1.11 billion, or $8.92 diluted EPS (vs. $1.87).
Results reflect lower operating expenses year over year and a $119 million discrete tax benefit, bringing the quarter’s reported tax rate to 16.6%. For the first half, revenue totaled $200.98 billion with net income attributable to McKesson of $1.89 billion and $15.16 diluted EPS. Cash from operations was $1.50 billion.
McKesson expanded its Oncology & Multispecialty segment with two deals: Core Ventures (70% for $2.5 billion) and PRISM Vision (80% for $871 million). It issued $2.0 billion of new notes (4.65% 2030, 4.95% 2032, 5.25% 2035) and ended the quarter with $4.00 billion in cash and $7.76 billion of total debt. The company classified its Norway businesses as held for sale, with net assets of $112 million. Shares outstanding were 123,426,650 as of October 31, 2025.